Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) have been given an average recommendation of “Moderate Buy” by the twelve analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $37.9286.

Several brokerages have issued reports on GMAB. The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 22nd. Wolfe Research began coverage on Genmab A/S in a research note on Friday, March 27th. They issued an “outperform” rating and a $32.00 price target on the stock. Wall Street Zen lowered Genmab A/S from a “buy” rating to a “hold” rating in a research note on Saturday, February 7th. Morgan Stanley began coverage on Genmab A/S in a research note on Monday, February 16th. They issued an “equal weight” rating and a $34.00 price target on the stock. Finally, BNP Paribas Exane raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 22nd.

Hedge Funds Weigh In On Genmab A/S

Several institutional investors have recently added to or reduced their stakes in GMAB. CIBC Private Wealth Group LLC lifted its stake in Genmab A/S by 291.9% in the fourth quarter. CIBC Private Wealth Group LLC now owns 827 shares of the company’s stock valued at $25,000 after buying an additional 616 shares during the period. Osaic Holdings Inc. raised its position in shares of Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock worth $33,000 after purchasing an additional 440 shares during the period. V Square Quantitative Management LLC acquired a new position in shares of Genmab A/S during the first quarter worth approximately $34,000. NewEdge Advisors LLC raised its position in shares of Genmab A/S by 1,229.0% during the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares during the period. Finally, Brown Brothers Harriman & Co. raised its position in shares of Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after purchasing an additional 780 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Stock Performance

Shares of GMAB stock opened at $24.73 on Friday. The business’s 50 day simple moving average is $26.92 and its 200 day simple moving average is $29.46. Genmab A/S has a one year low of $20.23 and a one year high of $35.43. The stock has a market capitalization of $15.42 billion, a PE ratio of 18.73, a PEG ratio of 1.42 and a beta of 0.85. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.